The efficacy and safety of intravenous tranexamic acid on blood loss during total ankle replacement: a retrospective study

Abstract

Only a few of studies have reported whether Tranexamic acid (TXA) has the same benefits during total ankle replacement as hip and knee replacements. In our study, we hypothesized that TXA was effective in reducing the perioperative blood loss without increasing the risk of symptomatic venous thromboembolism of patients during total ankle replacement. We retrospectively reviewed 71 patients who underwent total ankle replacement at the foot and ankle surgery center of our institution between January 2017 and May 2021. Patients were divided into two groups according to whether they received intravenous tranexamic acid or not. Patients who received intravenous TXA showed significantly lower estimated intraoperative blood loss, hidden blood loss and total blood loss. The early AOFAS score and ROM at the first month follow up of TXA group were better than the NO-TXA group and the incidence of early wound infection and poor healing (< 1 month postoperative) was significant lower than NO-TXA group. Use of TXA was not associated with significant changes in the incidence of postoperative symptomatic venous thromboembolism. We conclude that intravenous TXA can safely and effectively reduce perioperative blood loss and the incidence of early wound infection and poor healing in total ankle replacement, without increasing the risk of symptomatic venous thromboembolism.The application of TXA following total ankle replacement helped improve ankle function and patient quality of life during the early stage.

The effect of perioperative tranexamic acid (TXA) in patients with calcaneal fractures: a meta-analysis and systematic review of randomized controlled trials

“…Two trials [ 15 ] were deemed to be at low risk of bias and the other two trials were considered moderate [ 16 ]. All trials were judged at low risk of bias for the randomization process, and the selection bias in 2 trials [ 16 ] was unclear and so as in the performance bias. The detection bias was unclear in all trials (see in Table 3 ).…”

Use of Tranexamic Acid in Gender-Affirming Mastectomy Reduces Rates of Postoperative Hematoma and Seroma

“…Volume 153, Number 5 • TXA in Gender-Affirming Mastectomy 1003e Tranexamic acid (TXA) has emerged as a powerful adjunct for minimizing perioperative blood loss, with established safety and efficacy in cardiac, orthopedic, and trauma surgery, among other fields. [4][5][6][7][8][9] TXA is a synthetic lysine analogue that competitively inhibits the conversion of plasminogen to plasmin, thus preventing degradation of fibrin clots by plasmin. 10 TXA also blocks plasmin-induced platelet activation-thereby preserving platelets for clot formation-and serves as an anti-inflammatory agent.…”